Torii Pharmaceutical Co Ltd
TSE:4551
Torii Pharmaceutical Co Ltd
Other
Torii Pharmaceutical Co Ltd
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Torii Pharmaceutical Co Ltd
TSE:4551
|
Other
-¥1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Other
-¥129.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-30%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Other
-¥516m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
47%
|
CAGR 10-Years
8%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Other
¥12m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Other
¥113m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Astellas Pharma Inc
TSE:4503
|
Other
¥3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Torii Pharmaceutical Co Ltd
Glance View
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
See Also
What is Torii Pharmaceutical Co Ltd's Other?
Other
-1m
JPY
Based on the financial report for Jun 30, 2025, Torii Pharmaceutical Co Ltd's Other amounts to -1m JPY.
What is Torii Pharmaceutical Co Ltd's Other growth rate?
Other CAGR 10Y
10%
Over the last year, the Other growth was 50%.
